Evaluation of chemotherapy followed by multivalent dendritic cell vaccines and Ipilimumab for Stage IV metastatic melanoma.

Trial Profile

Evaluation of chemotherapy followed by multivalent dendritic cell vaccines and Ipilimumab for Stage IV metastatic melanoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Ipilimumab (Primary) ; Alpha galactosylceramide; Dendritic cell vaccines; Fotemustine; Picibanil; Zoledronic acid
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 26 Jan 2012 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 08 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top